Veracyte：核心增长产品Prosigna和TrueMRD推动业绩（纳斯达克：VCYT）
· seekingalpha.com
Veracyte（VCYT）2026年第二季度显示强劲的营收/EBITDA增长、现金流以及Prosigna/TrueMRD带来的上行潜力。探讨估值、护城河及业绩指引。
I believe Veracyte ( VCYT ) is now transitioning from a 2-product genomic testing business into a self-funded cancer diagnostic platform. The company's clinical...